Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
12.07(c)
11.6(c)
12.25(c)
13.83(c)
14.1 Last
985 411
535 738
597 405
817 356
803 008 Volume
-1.39% -3.89% +5.60% +12.90% +1.95% Change
Sales 2020
12,1 M - -
Net income 2020
-79,1 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
-8,10x
Yield 2020
-
Sales 2021
9,96 M - -
Net income 2021
-86,6 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
-8,51x
Yield 2021
-
Capitalization
777 M 777 M -
Capi. / Sales 2020
64,3x
Capi. / Sales 2021
78,0x
Nbr of Employees
83
Free-Float
93,4%
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a...
Notations Surperformance© of Syros Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
All news about SYROS PHARMACEUTICALS, INC.
News in other languages on SYROS PHARMACEUTICALS, INC.
- No features available -
Analyst Recommendations on SYROS PHARMACEUTICALS, INC.
Chart SYROS PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SYROS PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Average target price
17,43 $
Last Close Price
13,83 $
Spread / Highest target
44,6%
Spread / Average Target
26,0%
Spread / Lowest Target
-6,00%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
